abstract |
The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated lispro insulin compounds that are PEGylated with high molecular weight poly (ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and are characterized by peak-channel pharmacokinetic ratios. , pharmacodynamics, and / or activity of less than 2. The invention also relates to methods for providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses. |